Richard Kim, MD @MoffittNews #ASCO22 #OncoTwitter @oncoalert KEYNOTE-651 Long-Term Follow-Up

Richard Kim, MD @MoffittNews #ASCO22 #OncoTwitter @oncoalert KEYNOTE-651 Long-Term Follow-Up
Annual Meeting Photo

Annual Meeting
11 חודשים 17 צפיות

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract - Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D.


The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase 2 dose (RP2D): pembrolizumab plus binimetinib (Cohort A), pembrolizumab plus mFOLFOX7 (oxaliplatin 85 mg/m2; leucovorin [calcium folinate] 400 mg/m2; fluorouracil [5-FU] 2400 mg (Cohort E).